Dr. Doong was appointed CEO of ABVC on September 15, 2017. He also serves as the CEO and Chief Scientific Officer (“CSO”) of LifeCode Biotechnology Company (“LifeCode”), a Taiwan company that conducts medical research and provides cancer-related and genetic testing services. He served as the CSO of Cold Spring Biotech Corporation, a Taiwan based biotech company, from 2014 to 2016. He served as the Director of the Taipei Veteran General Hospital Laboratory of Cancer Genomic Medicine, a CAP-certified medical laboratory, from 2011 to 2013. Before Dr. Doong returned to Taiwan in 2011, he was a professor at the University of Maryland Medical School and a researcher at National Cancer Institute of the National Institutes of Health (NIH). He served as the Vice President of TrimGen Corporation, a manufacturer of molecular diagnostic reagents and medical instruments in Maryland. He was also a clinical research fellow at the Department of Surgery, University of Chicago Hospital.

Dr. Doong received his M.S. degree in Genetics from the University of New Hampshire. He received his Ph.D. degree from the University of Chicago, Department of Organismal Biology and Anatomy. He received his M.D and Ph.D. degree from Harvard-MIT Division of Health Sciences and Technology.